Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DDB1- and CUL4-associated factor 10 (DCAF10) is a WD repeat domain-containing protein that acts as a substrate receptor within the CUL4–DDB1 E3 ubiquitin ligase complex[1][3]. It is involved in targeting proteins for ubiquitination, a post-translational modification that leads to protein degradation via the ubiquitin–proteasome system[1][3]. DCAF10 plays a regulatory role in apoptosis, particularly by promoting the degradation of antiapoptotic proteins such as MCL1, thus activating caspase-dependent cell death pathways[1]. Downregulation or loss of DCAF10 has been observed in certain cancers, such as lung adenocarcinomas, suggesting its function in tumor suppression or oncogenesis[1]. It is also genetically associated with diseases like limb-girdle muscular dystrophy and corpus luteum cysts[3]. At present, DCAF10 is not considered a direct therapeutic target, and no drugs or biomarkers are reported to interact directly with it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DDB1- and CUL4-associated factor 10 (DCAF10).